cabiralizumab   Click here for help

GtoPdb Ligand ID: 9107

Synonyms: BMS-986227 | FPA-008 | FPA008
Immunopharmacology Ligand
Compound class: Antibody
Comment: Cabiralizumab is an investigational humanized monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is being investigated for its potential anti-cancer activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US20110274683 [1]
Click here for help
No information available.
Summary of Clinical Use Click here for help
Cabiralizumab (research code FPA008) is in early stage clinical trials for solid tumours and rheumatoid arthritis (RA). Click here to link to all FPA008 trials registered with Immuno-oncology trials are evaluating cabiralizumab monotherapy and combination with the immune checkpoint inhibitor nivolumab, anti-PD-1 mAb., in selected advanced solid tumours (Phase 1).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Anti-CSF1R antibodies prevent binding of the receptor's endogenous ligand CSF1 (or M-CSF). This action reduces monocyte infiltration into tumours and inhibits the acumulation of tumour-associated macrophages (TAMs). In RA anti-CSF1R antibodies are expected to reduce pro-inflammatory macrophage activity (and possibly osteoclast activity), to improve disease symptoms.